Wave Life Sciences Ltd. (WVE) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerns: a decline in revenue and increased R&D expenses and net loss. Despite the clinical pipeline progress, the market may react negatively to the financial results. The Q&A section highlights uncertainties in dosing strategies and management's reluctance to disclose specific milestone details, which could further erode investor confidence. The positive aspects, such as cash runway and pipeline advancements, are overshadowed by financial underperformance and lack of clarity in strategic execution.
Key Financial Performance
Revenue $8.7 million for Q2 2025, a decrease from $19.7 million in Q2 2024. The year-over-year decrease was due to the timing of revenue recognized under the collaboration agreement with GSK.
Research and Development Expenses $43.5 million for Q2 2025, an increase from $40.4 million in Q2 2024. The increase was primarily driven by spending in the INHBE program, RNA editing programs, and compensation-related expenses, including share-based compensation.
General and Administrative Expenses $18 million for Q2 2025, an increase from $14.3 million in Q2 2024. The increase was primarily related to share-based compensation and other external expenses.
Net Loss $50.5 million for Q2 2025, an increase from $32.9 million in Q2 2024. The increase was driven by higher R&D and G&A expenses.
Cash and Cash Equivalents $208.5 million as of the end of Q2 2025, a decrease from $302.1 million as of December 31, 2024. The decrease reflects operational spending.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
WVE-006 for AATD: Designed to address the root cause of alpha-1 antitrypsin deficiency (AATD) with a subcutaneous therapeutic. Demonstrated impressive durability and safety in trials, with data showing potential for monthly or less frequent dosing.
WVE-007 for obesity: Advanced INLIGHT clinical study with favorable safety and tolerability. Expanded second cohort dosing and initiated third cohort. Data expected to show healthy weight loss with infrequent dosing.
WVE-N531 for DMD: Demonstrated significant improvement in muscle health and function in boys with exon 53 amenable Duchenne muscular dystrophy (DMD). Plans to submit NDA in 2026 for accelerated approval.
WVE-003 for HD: Preparing for a Phase II/III study for Huntington's disease (HD) with allele-selective approach. Demonstrated potent mutant huntingtin reductions and correlation with slowing caudate atrophy.
RNA editing leadership: Continued leadership in RNA editing with advancements in clinical programs for AATD, obesity, and DMD.
Strategic partnerships: Actively engaged in discussions with prospective partners for HD program.
Financial performance: Revenue decreased to $8.7M from $19.7M YoY due to timing of collaboration revenue. Net loss increased to $50.5M from $32.9M YoY. Cash reserves at $208.5M, sufficient to fund operations into 2027.
R&D and G&A expenses: R&D expenses increased to $43.5M due to spending on INHBE and RNA editing programs. G&A expenses rose to $18M due to share-based compensation and external expenses.
Pipeline expansion: Advancing wholly owned discovery pipeline with new RNA editing and siRNA programs targeting hepatic and extrahepatic diseases. Clinical development of new programs expected in 2026.
Regulatory engagement: Positive FDA interactions for DMD and HD programs, aligning on next steps for accelerated approval and trial designs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company faces potential regulatory hurdles as it prepares for key data readouts and regulatory filings for its pipeline programs, including WVE-006 and WVE-003. The success of these filings is critical for advancing their clinical programs.
Financial Risks: The company reported a significant net loss of $50.5 million for Q2 2025, compared to $32.9 million in the prior year. This financial strain could impact its ability to sustain operations and fund ongoing research and development.
Pipeline Development Risks: There is uncertainty in the clinical outcomes of key programs such as WVE-006 for AATD and WVE-007 for obesity. The success of these programs is crucial for the company's strategic objectives.
Market Competition: The company faces competitive pressures, particularly in the obesity treatment market, where GLP-1 agonists are the current standard of care. Differentiating its product, WVE-007, will be essential to gain market share.
Supply Chain and Operational Risks: The company’s ability to rapidly recruit, enroll, and dose participants in clinical trials is critical. Any disruptions in these processes could delay key data readouts and impact strategic timelines.
Economic and Funding Risks: The company’s cash and cash equivalents decreased significantly from $302.1 million at the end of 2024 to $208.5 million in Q2 2025. While the company expects to fund operations into 2027, this is contingent on achieving milestones and securing additional funding.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
WVE-006 for AATD: Data from the complete 200-milligram single and multi-dose cohorts will be delivered in Q3 2025, and single-dose data from the 400-milligram cohort will be available in fall 2025. Multi-dose data will inform the therapeutic potential and dosing intervals for WVE-006.
WVE-007 for Obesity: Data from the expanded 240-milligram second dose cohort and the 75-milligram Cohort 1 will be delivered in Q4 2025. Data from the 400-milligram third dose cohort will be available in Q1 2026. The program aims to demonstrate healthy weight loss with infrequent dosing.
WVE-N531 for DMD: An NDA submission for accelerated approval is planned for 2026, with a monthly dosing regimen. A global confirmatory trial design is also planned.
WVE-003 for HD: A global Phase II/III study is planned for submission in the second half of 2025, using caudate volume as a primary endpoint. The study aims to address the full spectrum of HD with an allele-selective approach.
Pipeline Expansion: New clinical programs are expected to be initiated in 2026, including RNA editing and siRNA programs targeting hepatic and extrahepatic tissues.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
dividend program: No mention of a dividend program was made during the conference call.
shares buyback program: No mention of a shares buyback program was made during the conference call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:For the INHBE program, can you elaborate on your reasons for expanding Cohort 2 over advancing to Cohort 3 sooner? If the Cohort 2 dose was well tolerated, why not just advance to Cohort 3 versus expanding Cohort 2? And also, when you say Cohort 2 dose is therapeutically relevant, is that in reference to semaglutide-like weight loss? Is the goal of Activin E knockdown around 50% based on your human heterozygotes having the protective phenotype?
A:The decision to expand Cohort 2 was based on the dose being modeled in the clinic to align with weight loss similar to semaglutide based on the DIO model. The Cohort 2 dose was therapeutically relevant and showed in excess of 50% reduction of Activin E in preclinical models. The expansion to 32 patients was to enrich the dataset for assessing weight loss. Cohort 3 at 400 mg is already underway, driven by safety data allowing dose escalation.
Q:Should we be expecting a linear dose response? Or does the preservation of lean mass offset the weight loss aspect as you go to Cohort 3?
A:In the animal model, weight loss comparable to GLP-1s was observed, driven by fat reduction without muscle impact. The human experience will determine how linear the translation is. The expansion of Cohort 2 to 32 patients aims to assess weight loss, which is over three times higher than the first cohort.
Q:What is your guidance on the different expectations from the 006 AATD data readout in 3Q and 4Q? Should we focus more on the absolute level of M-protein production versus the percentage of the total protein?
A:The 200 mg multi-dose data is expected to provide larger liver exposure compared to the 200 mg single dose. M-protein is critical to follow as it is standardized and indicates editing efficiency and therapeutic levels. Total protein levels will also be assessed for additional insights.
Q:For the 007 INHBE data readout, how much kinetics and durability of weight loss and biomarker change can we observe from the initial data readout in 4Q?
A:At least 3 months of follow-up on Cohorts 1 and 2 will be available at the data readout. Subsequent readouts for the 400 mg dose are expected in Q1 of 2026.
Q:What would you see as a desirable knockdown level for INHBE, and do you have a plan to continue dose escalation after Cohort 3?
A:The modeling aligns with preclinical data, and Cohort 2 was designed to replicate the DIO mouse model. The 400 mg Cohort 3 is underway, and dose escalation may continue if required. The current cohorts straddle the model well, and safety data supports the potential for higher doses.
Q:Would the recent updates at the FDA level affect your approach or strategy for the DMD program?
A:The program goes to CDER, which established the threshold for accelerated approvals for exon skipping therapies. There is no indication of changes to the approach or strategy based on recent FDA updates.
Q:Can you be specific about when dosing was completed for the 200 mg multi-dose in the AATD program? Did all patients receive all seven doses?
A:All patients received seven doses with follow-up. The study was executed as designed, and data remains on track for the third quarter.
Q:When you mentioned dosing was complete with the first 2 cohorts of INLIGHT, was this before or after the expansion of Cohort 2 was triggered?
A:The update was before the expansion of Cohort 2. The expansion from 8 to 32 patients was triggered based on data thresholds met in the quarter.
Q:Is there anything qualitatively about the consistency of effect for the dose patients in both single dose and multi-dose cohorts in AATD?
A:The GalNAc distribution to cells has been consistent, with substantial protein production observed preclinically. Early proof-of-mechanism data in humans also shows consistency, and the 200 mg multi-dose data will provide a comprehensive assessment.
Q:Are the GalNAc AIMers behaving similar to GalNAc siRNAs in terms of clinical translation at the level of PK/PD?
A:GalNAc distribution is consistent across modalities, and the modeling is efficient in predicting exposures. The retention of the drug in cells and its stability are optimized for catalytic enzyme engagement, supporting long-term durability and efficacy.
Q:What are the takeaways from the bimagrumab Phase II data at ADA, and how does it influence the development of 007?
A:The data highlights the importance of muscle preservation and fat reduction. INHBE offers a clean pathway to reduce visceral fat and preserve muscle with a favorable safety and tolerability profile. The focus is on delivering healthy, sustainable weight loss with infrequent subcutaneous administration.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the potential milestones from GSK related to the 006 program, stating they could not disclose how milestone payments are allocated. Additionally, they did not provide clarity on the exact dosing frequency for the INHBE program, indicating that more data is needed to determine the interval.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
American Diabetes
Association Conference
Chief Medical
Cohort safety
Day fall
Diabetes Association
Dr
GalNAc siRNA
INLIGHT dos
INLIGHT milligram
Inc Research
LLC Research
Medical Officer
Research Day
Research Division
RestorAATion
Securities Inc
action genetics
balance
cardiometabolic health
cohort INLIGHT
cohort participant
compensation
date escalate
dos adult
dose participant
escalate milligram
factor drug
loss addition
measurement weight
milligram Cohort
patient milligram
reduction Cohort
semaglutide
standard care
tolerability profile
volume
WVE Transcript
Wave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call summary reveals a mixed sentiment. While there are positive developments in product pipeline and strategic alignment with regulatory pathways, the lack of clear guidance on key metrics like fat loss and biomarker data, coupled with management's avoidance of direct answers, creates uncertainty. The Q&A section highlights cautious optimism but also reveals potential risks and uncertainties. Without a market cap context, it's challenging to predict a strong movement, thus a neutral stance is appropriate.
Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call summary indicates a mix of positive and cautious elements. While there are promising developments in product pipelines and strategic plans, there are also uncertainties, particularly in the obesity program and AATD study. The Q&A highlighted management's avoidance of specifics, which may raise concerns. No strong catalysts like partnerships or record revenues were mentioned, and the strategic plan lacks immediate financial impact. The absence of market cap data limits assessment of stock sensitivity, but overall sentiment leans towards neutral given the balanced positives and uncertainties.
WVE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
